Marksans Pharma Ltd

Marksans Pharma Ltd share price gained 2.74% to Rs 278.9 after the company's net profit saw a marginal increase of 6.97% to Rs 159.41 crore, while revenue from operations eased by 1.79% to Rs 840.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, easing 4.41%. It has marginally improved by 1.16% over last one week and moving up by 11.70% in last one month while the market capitalization of Marksans Pharma Ltd has improved by 3.11% and 38% in the same period respectively. Profit before tax (PBT) of Marksans Pharma Ltd stood at Rs 206.57 crore in Q2 FY26, rallying 169.67% year-on-year, and gaining 3.28% quarter-on-quarter. EBITDA came in at Rs 188 crore, surging by 98.59% YoY and expanding by 17.09% sequentially. Total expenses softened by 4.72% to Rs 652.63 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 220.67 crore, contracting by 16.72% YoY, while employee benefits expense was at Rs 114.29 crore, rising by 7.05% YoY. For the TTM ended FY26, revenue from operations improved 12.51% to Rs 2950.94 crore, while net profit saw a mild growth of 9.79% to Rs 420.06 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 48060% to Rs 518.25 crore, and PBT registered a growth of 11.23% to Rs 560.56 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 458.13 crore in FY26, as against Rs 206.66 crore in FY25. Marksans Pharma Ltd rallied 32.97% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.04% during the same period.

Marksans Pharma’s annual report indicates the company maintains a focus on product quality and ethical business practices, reporting no adverse orders, customer complaints, product recalls, or data breaches. The company engages with local communities through meetings and grievance redressal mechanisms, and has a framework in place for cybersecurity and data privacy. Input materials are sourced with 4.86% directly from micro and small enterprises, 65.70% from other Indian suppliers, and 29.44% through imports. Employment is heavily concentrated in urban and metropolitan areas, accounting for 74.77% and 25.23% of the workforce respectively. Marksans Pharma is exploring corporate social responsibility initiatives in health and education, and 100% of its formulation products include information on safe usage, accessible via www.marksanspharma.com.

Marksans Pharma Ltd. will hold a board meeting on Wednesday, August 12, 2026, in Mumbai to consider and approve the unaudited financial results for both standalone and consolidated entities for the quarter ended June 30, 2026, according to a regulatory filing. The company has closed the trading window for its designated persons, including directors, from July 1, 2026, until August 14, 2026, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Marksans Pharma Ltd lost 5.24% today to trade at Rs 246.7. The BSE Healthcare index is down 1.34% to quote at 49789.55. The index is up 3.23 % over last one month. Among the other constituents of the index, Anthem Biosciences Ltd decreased 5.17% and Bajaj Healthcare Ltd lost 4.07% on the day. The BSE Healthcare index went up 11.39 % over last one year compared to the 5.84% fall in benchmark SENSEX. Marksans Pharma Ltd has lost 3.67% over last one month compared to 3.23% gain in BSE Healthcare index and 0.38% rise in the SENSEX. On the BSE, 55408 shares were traded in the counter so far compared with average daily volumes of 1.58 lakh shares in the past one month. The stock hit a record high of Rs 281.4 on 09 Jul 2026. The stock hit a 52-week low of Rs 156 on 30 Mar 2026.Powered by Capital Market - Live

Marksans Pharma has completed the process of acquiring 100% share capital of ABCnow GmbH based in Germany.

Marksans Pharma has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. The company will acquire entire shareholding of ABCnow GmbH for a total consideration of ' 892,384. The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union. This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans' presence in the European markets.

Headquartered in Flensburg, ABCnow GmbH is a pharmaceutical company with front end sales, marketing, and distribution capabilities across German healthcare market. It has a turnover of euro 227,233.69 as on 31 December 2025. Marksans will acquire entire shareholding of ABCnow GmbH for a total cash consideration of euro 892,384. The acquisition is expected to be completed by 31 July 2026. Offering the rationale for this acquisition, Marksans Pharma stated that this acquisition will enable the company to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans' presence in the European markets. Marksans Pharma is engaged in the research, manufacturing and marketing of pharmaceutical formulations across regulated and emerging markets, with a strong presence in OTC and prescription products. The company had reported 63.59% increase in consolidated net profit to Rs 148.13 crore on a 20.84% rise in revenue to Rs 856.11 crore in Q4 FY26 as compared with Q4 FY25. Powered by Capital Market - Live

Marksans Pharma announced that the 34th Annual General Meeting(AGM) of the company will be held on 27 August 2026.

Marksans Pharma has completed the acquisition of 100% share capital of QliniQ B.V. based in the Netherlands.

Marksans Pharma has received affirmation in credit ratings for bank facilities at IND AA-/ IND A1+ while outlook has been revised to 'Positive' from 'Stable'.